VTYX - long - catalysts and gap - amazing R/R

Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. Its lead product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.

This is not a financial advice!

Recent block buy

Upcoming catalyst end of March 2024

Low float of 44.47M
Short float 11.20%

Keep an eye on 2.80 level - needs to get broken for a further upmove.

SL under 1.8

Potenential gap fill: TP approx. 14 -15

Most info on the chart.

Trade carefully!

Comment:

uhh it's getting hot

Trade closed: target reached:

booom what a trade!